ISPOR - PCN76 Economic Evaluation of the Use of Erlotinib for Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutation in Mexican Public Health Institutions

Full Text

PCN76 Economic Evaluation of the Use of Erlotinib for Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutation in Mexican Public Health Institutions

Abstract

Authors

D. Lechuga M. Alva J.G. Gay R. Sánchez-Kobashi

Back to Volume 15, Issue 4

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now